196 related articles for article (PubMed ID: 25942376)
1. Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment.
Zhang C; Hong CS; Hu X; Yang C; Wang H; Zhu D; Moon S; Dmitriev P; Lu J; Chiang J; Zhuang Z; Zhou Y
Cell Cycle; 2015; 14(13):2100-8. PubMed ID: 25942376
[TBL] [Abstract][Full Text] [Related]
2. The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.
Chang KE; Wei BR; Madigan JP; Hall MD; Simpson RM; Zhuang Z; Gottesman MM
Mol Cancer Ther; 2015 Jan; 14(1):90-100. PubMed ID: 25376608
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus.
Liu L; Wang H; Cui J; Zhang Q; Zhang W; Xu W; Lu H; Liu S; Shen S; Fang F; Li L; Yang W; Zhuang Z; Li J
Cell Physiol Biochem; 2018; 50(1):317-331. PubMed ID: 30282066
[TBL] [Abstract][Full Text] [Related]
4. PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells.
Ho WS; Feldman MJ; Maric D; Amable L; Hall MD; Feldman GM; Ray-Chaudhury A; Lizak MJ; Vera JC; Robison RA; Zhuang Z; Heiss JD
Oncotarget; 2016 Mar; 7(11):12447-63. PubMed ID: 26799670
[TBL] [Abstract][Full Text] [Related]
5. LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential.
Hong CS; Ho W; Zhang C; Yang C; Elder JB; Zhuang Z
Cancer Biol Ther; 2015; 16(6):821-33. PubMed ID: 25897893
[TBL] [Abstract][Full Text] [Related]
6. Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.
Gordon IK; Lu J; Graves CA; Huntoon K; Frerich JM; Hanson RH; Wang X; Hong CS; Ho W; Feldman MJ; Ikejiri B; Bisht K; Chen XS; Tandle A; Yang C; Arscott WT; Ye D; Heiss JD; Lonser RR; Camphausen K; Zhuang Z
Mol Cancer Ther; 2015 Jul; 14(7):1540-1547. PubMed ID: 25939762
[TBL] [Abstract][Full Text] [Related]
7. Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.
Hao S; Song H; Zhang W; Seldomridge A; Jung J; Giles AJ; Hutchinson MK; Cao X; Colwell N; Lita A; Larion M; Maric D; Abu-Asab M; Quezado M; Kramp T; Camphausen K; Zhuang Z; Gilbert MR; Park DM
Neuro Oncol; 2018 May; 20(6):799-809. PubMed ID: 29294092
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PP2A by LB100 sensitizes bladder cancer cells to chemotherapy by inducing p21 degradation.
Gao S; Shan L; Zhang M; Wang Y; Zhan X; Yin Y; Jiang Z; Tao X; Li X; Ye M; Liu Y
Cell Oncol (Dordr); 2022 Dec; 45(6):1203-1215. PubMed ID: 36136269
[TBL] [Abstract][Full Text] [Related]
9. Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Zhu DW; Yuan YX; Qiao JK; Yu C; Yang X; Wang LZ; Zhang ZY; Zhong LP
Cancer Lett; 2015 Jan; 356(2 Pt B):773-80. PubMed ID: 25449438
[TBL] [Abstract][Full Text] [Related]
10. LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.
Ho WS; Sizdahkhani S; Hao S; Song H; Seldomridge A; Tandle A; Maric D; Kramp T; Lu R; Heiss JD; Camphausen K; Gilbert MR; Zhuang Z; Park DM
Cancer Lett; 2018 Feb; 415():217-226. PubMed ID: 29199006
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair.
Lv P; Wang Y; Ma J; Wang Z; Li JL; Hong CS; Zhuang Z; Zeng YX
Oncotarget; 2014 Sep; 5(17):7512-24. PubMed ID: 25245035
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair.
Wei D; Parsels LA; Karnak D; Davis MA; Parsels JD; Marsh AC; Zhao L; Maybaum J; Lawrence TS; Sun Y; Morgan MA
Clin Cancer Res; 2013 Aug; 19(16):4422-32. PubMed ID: 23780887
[TBL] [Abstract][Full Text] [Related]
13. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
14. Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
Mirzapoiazova T; Xiao G; Mambetsariev B; Nasser MW; Miaou E; Singhal SS; Srivastava S; Mambetsariev I; Nelson MS; Nam A; Behal A; Arvanitis LD; Atri P; Muschen M; Tissot FLH; Miser J; Kovach JS; Sattler M; Batra SK; Kulkarni P; Salgia R
Mol Cancer Ther; 2021 Oct; 20(10):1820-1835. PubMed ID: 34253596
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Otani Y; Sur HP; Rachaiah G; Namagiri S; Chowdhury A; Lewis CT; Shimizu T; Gangaplara A; Wang X; Vézina A; Maric D; Jackson S; Yan Y; Zhengping Z; Ray-Chaudhury A; Kumar S; Ballester LY; Chittiboina P; Yoo JY; Heiss J; Kaur B; Banasavadi-Siddegowda YK
Neuro Oncol; 2021 Sep; 23(9):1481-1493. PubMed ID: 33556161
[TBL] [Abstract][Full Text] [Related]
16. The effect of protein phosphatase 2A inhibitor LB100 on regulating methamphetamine induced conditioned place preference in mice.
Qian H; Wang J; Shang Q; Xiao J; Chen G; Gao B; Liang M; Li T; Liu X
Neurosci Lett; 2020 Mar; 721():134817. PubMed ID: 32032748
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas.
Bai XL; Zhang Q; Ye LY; Hu QD; Fu QH; Zhi X; Su W; Su RG; Ma T; Chen W; Xie SZ; Chen CL; Liang TB
Mol Cancer Ther; 2014 Aug; 13(8):2062-72. PubMed ID: 24867249
[TBL] [Abstract][Full Text] [Related]
18. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
[TBL] [Abstract][Full Text] [Related]
20. Caffeine citrate enhanced cisplatin antitumor effects in osteosarcoma and fibrosarcoma in vitro and in vivo.
Abe K; Yamamoto N; Hayashi K; Takeuchi A; Tsuchiya H
BMC Cancer; 2019 Jul; 19(1):689. PubMed ID: 31307409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
